- Disease: Mpox
- Study type: Randomised Clinical Trial, Adaptive Platform Trial, Treatment
- Study type descriptors: Interventional
- Objective: To evaluate the clinical efficacy and safety of tecovirimat treatment in patients with mpox
- Number of participants enrolled: Enrollment data not available
- Study enrolling from to
- Study includes follow-up for 2 months
Sites (11)
- Centro de Referência e Treinamento DST/AIDS-SP (São Paulo, Brazil)
- University Hospital of Geneva (Geneva, Switzerland)
- Hospital Federal dos Servidores do Estado (Rio de Janeiro, Brazil)
- Federal University of Minas Gerais (Belo Horizonte, Brazil)
- Complexo Hospitalar Universitário Professor Edgard Santos (Salvador, Brazil)
- Nova Iguaçu General Hospital (Rio de Janeiro, Brazil)
- Instituto de Infectologia Emílio Ribas (São Paulo, Brazil)
- Fundación Huésped (Buenos Aires, Argentina)
- Checkpoint Zurich (Zurich, Switzerland)
- Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland)
- Evandro Chagas National Institute of Infectious Diseases (Rio de Janeiro, Brazil)
Study Data
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Antivirals
- Tecovirimat
External Links
Other information
Funders/Sponsors:
- ANRS Emerging Infectious Diseases
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to